Company profile for Imunon

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACC...
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648
Telephone
Telephone
(609) 896-9100
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/13/3187221/0/en/IMUNON-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
13 Nov 2025

https://www.globenewswire.com/news-release/2025/11/10/3184931/0/en/IMUNON-Public-Webcast-Highlights-Resilience-and-Innovation-in-Pursuit-of-the-First-Approved-Immunotherapy-for-Ovarian-Cancer.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/11/10/3184427/0/en/IMUNON-R-D-Day-Showcases-Clinical-Progress-of-Its-Novel-Immunotherapy-Phase-3-Trial-and-Significant-Potential-for-Women-with-Ovarian-Cancer.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/11/07/3183619/0/en/IMUNON-R-D-Day-Opportunity-to-Hear-Clinical-Trial-Investigators-Discuss-Significant-Potential-of-IMNN-001-to-Redefine-Ovarian-Cancer-Treatment.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/11/06/3182557/0/en/IMUNON-to-Hold-Third-Quarter-2025-Financial-Results-and-Business-Update-Conference-Call-on-Thursday-November-13-2025.html

GLOBENEWSWIRE
06 Nov 2025

https://www.globenewswire.com/news-release/2025/11/04/3180312/0/en/IMUNON-Announces-Webcast-of-In-Person-R-D-Day-Highlighting-Progress-on-OVATION-3-Study-in-Pursuit-of-First-Frontline-Immunotherapy-for-Advanced-Ovarian-Cancer.html

GLOBENEWSWIRE
04 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty